看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。. O" Y6 P% f! f! D' y$ @/ s
0 }; u: l4 o( ?% \- P
4 Y C: c8 n, a4 iCurrently available feasibility data for possible combination strategies.
. M' ]4 D; u: ^+ Z ~( ?————————————————————————————————
6 E6 q# e5 n4 O2 z5 |9 S# _Combination Feasibility according to preliminary data
- _2 f* [" |* u; {8 {——————————————————————————————————
( C9 d& Z& P$ U7 R8 zBevacizumab + sorafenib Yes, reduced dose
# J) b; c( |% @) x1 V3 j4 tBevacizumab + sunitinib† No " a; m4 r4 e7 p O9 }
Bevacizumab + temsirolimus Yes
# h3 J2 ?8 Z4 h' F5 A8 @Bevacizumab + everolimus Yes : f( f, c# d6 ]( K
Sorafenib + sunitinib ?
. T+ I( g: ~6 h* L# |4 t/ HSorafenib + temsirolimus Yes, reduced dose
) a; s( ~1 W8 M- I6 L) [Sorafenib + everolimus Yes, reduced dose
2 T" P2 [: B# I- _Sunitinib + temsirolimus† No
2 N( b/ j! a$ b+ Y, ?: USunitinib + everolimus ? % D# }( {8 y% @. }% m& l3 i4 d
Temsirolimus + everolimus ?
( \6 U6 x- B, a3 D, w. \————————————————————! d+ C3 A6 P `! M, ^( _4 N6 q
†Led to US FDA warning./ `) p% b ?' Q% b8 z
?: As yet unattempted combination.
. J Q9 E0 W$ { |